Discover

TEVA
Teva Pharmaceutical Industries Limited
37.09
300 x 36.98
300 x 37.03
bid
ask
+
0.74
2.04%
300 @ 05:32 PM
37.09 +0.00 (0.00%)
Ytd18.84%
1y86.48%
36.06
day range
37.09
18.34
52 week range
38.10
Open36.46Prev Close36.35Low36.06High37.09Mkt Cap43.22B
Vol2.86MAvg Vol5.46MEPS0.60P/E61.82Forward P/E12.09
Beta0.87Short Ratio7.38Inst. Own64.47%DividendN/ADiv YieldN/A
Ex Div Date11-27Earning11-0450-d Avg34.81200-d Avg32.761yr Est41.91
Earning
DateForEstimateReportedSurprisesurprise %
2026-11-042026-090.71N/AN/AN/A
2026-07-292026-060.080.02-0.06-75.00%
2026-04-292026-030.50.530.036.00%
2026-01-282025-120.650.960.3147.69%
2025-11-052025-090.680.780.114.71%
2025-07-302025-060.630.660.034.76%
Upgrade / Downgrade
DateFirmActionFromTo
2026-09-09Leerink PartnersUpgradeOutperform
2026-09-04UBSUpgradeBuyBuy
2026-08-12BarclaysUpgradeOverweightOverweight
2026-07-28Piper SandlerUpgradeOverweightOverweight
2026-05-06BarclaysUpgradeOverweightOverweight
2026-04-30JP MorganUpgradeOverweightOverweight
Profile
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Insider Holder
DateNameRelationQuantityDescription
2025-06-05CRANE ROSEMARY ADirector113.25KConversion of Exercise of derivative security
2026-03-02DANIELL RICHARDOfficer123.13KSale
2025-06-05ELSTEIN AMIRDirector2.10MConversion of Exercise of derivative security
2026-03-04FRANCIS RICHARD DChief Executive Officer1.17MSale
2026-03-04HUGHES ERIC AOfficer107.71KSale
2026-03-04KALIF ELIYAHU SHARONChief Financial Officer325.44KConversion of Exercise of derivative security
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-06-29Blackrock Inc.63.89M2.37B5.48%
2026-06-29Harel Insurance Investments & Financial Services Ltd.48.14M1.79B4.13%
2026-06-29Phoenix Financial Ltd.42.93M1.59B3.68%
2026-06-29WCM Investment Management, LLC41.32M1.53B3.55%
2026-06-29Clal Insurance Enterprises Holdings Ltd40.60M1.51B3.48%
2026-06-29Menora Mivtachim Holdings Ltd.39.85M1.48B3.42%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-06-29INVESTMENT MANAGERS SERIES TRUST-WCM Focused International Growth Fund13.25M491.71M1.14%
2026-06-29New Economy Fund9.41M349.14M0.81%
2026-06-29iShares Trust-iShares Core MSCI EAFE ETF8.65M320.89M0.74%
2026-07-30Fidelity Concord Street Trust-Fidelity International Index Fund4.53M167.95M0.39%
2026-06-29New World Fund Inc4.31M159.76M0.37%
2026-07-30Fidelity Rutland Square TRT II-Strategic Advisers Fidelity Intl Fd.4.36M161.64M0.37%
Dividend
DividendDate
0.0852017-11-27
0.0852017-08-25
0.342017-06-01
0.342017-02-28
0.342016-12-01
0.342016-08-18
Split
SplitDate
2 : 12004-07-01
2 : 12002-12-06
2 : 12000-02-23
2 : 11993-04-14
1 : 11982-08-16